Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 19 Lung Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 2 Ovarian Neoplasms 2 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Squamous-Cell Lung Cancer 1 Small Cell Lung Carcinoma 1 Retinoblastoma 1 Retinal Neoplasms 1 Resectable Lung Non-Small Cell Carcinoma 1 Recurrence 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Ovarian Cancer Recurrent 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 NSCLC 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1 Carcinoma, Bronchogenic 1 Bronchial Neoplasms 1 Advanced Non Small Cell Lung Cancer 1 Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 58 Dexamethasone 50 Rituximab 39 Peripheral Blood Stem Cell Transplantation 29 Paclitaxel 29 Lenalidomide 28 fludarabine phosphate 27 Gemcitabine 26 Etoposide 26 Bortezomib 26 Cytarabine 25 Busulfan 24 pembrolizumab 21 Radiotherapy 21 Bevacizumab 21 Carboplatin 20 Mycophenolic Acid 19 Melphalan 19 Cisplatin 19 Filgrastim 18 pomalidomide 17 fludarabine 17 Oxaliplatin 17 Antilymphocyte Serum 17 Cyclosporine 16 Tacrolimus 15 Methotrexate 15 Whole-Body Irradiation 14 Methylprednisolone 13 Bendamustine Hydrochloride 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Recurrence × Platinum Compounds × Clear all

NCT07340164 2026-04-20

TROY

Yonsei University

Phase 2 Recruiting

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡